Literature DB >> 2845125

Activation of the human immunodeficiency virus long terminal repeat by herpes simplex virus type 1 is associated with induction of a nuclear factor that binds to the NF-kappa B/core enhancer sequence.

J M Gimble1, E Duh, J M Ostrove, H E Gendelman, E E Max, A B Rabson.   

Abstract

It has been previously shown that herpes simplex virus type 1 (HSV-1) infection of HeLa cells results in augmentation of gene expression directed by the human immunodeficiency virus (HIV) long terminal repeat (LTR). This effect is presumably mediated by protein interactions with the LTR. We have used two different assays of DNA-protein interactions to study the HSV-induced activation of the HIV LTR. Activation of the HIV LTR is associated with increased protein binding to LTR sequences in a region including the NF-kappa B/core enhancer and the Sp1 binding sequences as monitored by an exonuclease protection assay. Gel retardation assays demonstrated that HSV-1 infection resulted in the induction of a nuclear factor(s) that binds to the NF-kappa B/core enhancer sequence. In addition to the activation of the HIV LTR, HSV induction of NF-kappa B activity may be important for the regulation of HSV gene expression during a herpesvirus infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845125      PMCID: PMC253841     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Characterization of long terminal repeat sequences of HTLV-III.

Authors:  B Starcich; L Ratner; S F Josephs; T Okamoto; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

2.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

3.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

4.  Purification, structure, and properties of hybrid beta-galactosidase proteins.

Authors:  A V Fowler; I Zabin
Journal:  J Biol Chem       Date:  1983-12-10       Impact factor: 5.157

5.  Eukaryotic gene transcription with purified components.

Authors:  J D Dignam; P L Martin; B S Shastry; R G Roeder
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

7.  A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus.

Authors:  M Boshart; F Weber; G Jahn; K Dorsch-Häsler; B Fleckenstein; W Schaffner
Journal:  Cell       Date:  1985-06       Impact factor: 41.582

8.  Multiple point mutations affecting the simian virus 40 enhancer.

Authors:  H Weiher; M König; P Gruss
Journal:  Science       Date:  1983-02-11       Impact factor: 47.728

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus.

Authors:  J A Garcia; F K Wu; R Mitsuyasu; R B Gaynor
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  33 in total

1.  Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication.

Authors:  T I McLean; S L Bachenheimer
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression.

Authors:  S Rasty; P Thatikunta; J Gordon; K Khalili; S Amini; J C Glorioso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  The role of free radical scavengers, inhibitors of prostaglandin synthesis, and hypomethylating agents in reactivation of latent herpes simplex virus.

Authors:  S Sienko; A M Eis-Hübinger; K E Schneweis
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

5.  The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent.

Authors:  E B Quinlivan; E Holley-Guthrie; E C Mar; M S Smith; S Kenney
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

Review 6.  Immunopathology of human immunodeficiency virus infection in the gastrointestinal tract.

Authors:  T Schneider; R Ullrich; M Zeitz
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Identification and characterization of a human herpesvirus 6 gene segment capable of transactivating the human immunodeficiency virus type 1 long terminal repeat in an Sp1 binding site-dependent manner.

Authors:  J Wang; C Jones; M Norcross; E Bohnlein; A Razzaque
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  The presence of tat protein or tumor necrosis factor alpha is critical for herpes simplex virus type 1-induced expression of human immunodeficiency virus type 1.

Authors:  W Popik; P M Pitha
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  Activation of the cellular transcription factor AP-1 in herpes simplex virus infected cells is dependent on the viral immediate-early protein ICPO.

Authors:  K L Jang; B Pulverer; J R Woodgett; D S Latchman
Journal:  Nucleic Acids Res       Date:  1991-09-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.